Press Release — Jun. 03, 2022
TORONTO, ON – June 2, 2022 – (Canada Newswire) The board of directors of Psychedelics Canada, speaking on behalf of legal psychedelic medicine and therapy companies, strongly supports the decision by the Government of Canada to grant British Columbia’s request to decriminalize personal possession of small amounts of certain illicit substances in that province.
“Our role is to develop legal, therapeutic treatments using psychedelic medicines,” said Nick Kadysh, CEO of PharmAla Biotech, and Board Chair of Psychedelics Canada. “While our focus is on medical applications in therapeutic settings by qualified professionals, rather than personal or recreational use, we are strong believers in harm reduction. Criminalizing addiction is not good public policy, and some of the drugs in question have a very low risk factor and abuse liability potential.”
Psychedelics Canada was formed to advocate on behalf of patients, manufacturers, clinics, and researchers in the legal psychedelics industry. Its members work collaboratively with government, the press, and the public to pursue the research, development and application of psychedelic medicines in Canada.
“We applaud the government for this milestone,” said Liam Bedard, Coordinator of Psychedelics Canada. “We look forward to engaging with Health Canada on the Canadian Drugs and Substances Strategy, and on the potential applications of psychedelic medicine and therapies in the near future.”
Liam Bedard, Coordonnateur